VanEck Pharmaceutical ETF
PPH
60 hedge funds and large institutions have $177M invested in VanEck Pharmaceutical ETF in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 19 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
26% more capital invested
Capital invested by funds: $141M → $177M (+$36.4M)
11.77% more ownership
Funds ownership: 40.69% → 52.45% (+12%)
3% more funds holding
Funds holding: 58 → 60 (+2)
8% less call options, than puts
Call options by funds: $419K | Put options by funds: $454K
32% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$39M |
| 2 |
Goldman Sachs
New York
|
+$17.1M |
| 3 |
VF
Virtu Financial
New York
|
+$2.42M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.27M |
| 5 |
LCM
LVM Capital Management
Portage,
Michigan
|
+$461K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$6.83M |
| 2 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$3.26M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$3.03M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.28M |
| 5 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$2.07M |
PPH Hedge Fund Activity: Q3 2016 in Review
60 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q3 2016, worth a combined $177M — up 26% from $141M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PPH positions and 4 closed out — a net gain of 3 holders — while 13 added to existing stakes and 19 trimmed.
The largest buyer was Citigroup, adding an estimated $39M. The largest seller was Morgan Stanley, cutting an estimated $6.83M.
- 60 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q3 2016, up from 58 in Q2 2016.
- Funds reported $177M of VanEck Pharmaceutical ETF stock for Q3 2016, up 26% quarter-over-quarter.
- 7 funds opened new VanEck Pharmaceutical ETF positions in Q3 2016 and 4 closed out, a net change of +3 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q3 2016 was Citigroup, an estimated $39M added.
- The largest VanEck Pharmaceutical ETF seller in Q3 2016 was Morgan Stanley, an estimated $6.83M sold.
Based on aggregated 13F filings for Q3 2016.